Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation...

